摘要 |
This invention describes compounds of Formula (I), or a pharmaceutically accepted salt thereof, wherein each R3 and R4 is independently H, halogen or C1-4aliphatic optionally substituted with halogen, C1-2aliphatic, OCH 3, NO2, NH2, CN, NHCH3, SCH 3, or N(CH)2. R2 is a 3-8membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R2 is optionally substituted with JR; each X1 and X2 is independently-C(O)-,-NR-, or-SO2-wherein one of X1 or X2 is-NR-and other of X1 or X2 is-C(O)-or-SO 2-; R1 and R are as described herein; These compounds are effective as inhibitors of Tec family (e.g., Tec, Btk, Itk/Emt/Tsk, Bmx, Txk/Rlk) protein kinases. These compounds and pharmaceutically acceptable compositions thereof are useful for treating or preventing a variety of diseases, disorders or conditions, including, but not limited to, an autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunologically-mediated disease.
|